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Specific drug delivery is one of the main objectives of current medicine 
since side effects get reduced. Virus nanoparticles (VNPs) are a 
promising drug delivery vehicle as they are small, well-characterized 
and biocompatible. 
 
Plant virus like cowpea mosaic virus (CPMV) are interesting VNPs 
because they are considered non-infectious and nonhazardous in 
mammals. CPMV is member of family Comoviridae and infects the 
cowpea plant (Vigna unguiculata). It has a diameter of 30 nm and a 
bipartite positive-strand genome. 
 
The methodology of the report was to search for scientific literature in 
the PubMed database with the aim of understanding what is known 
about CPMV and discussing how it can help in the treatment of diseases 
such as cancer. 
 
CPMV genome is formed by two strands, RNA-1 and RNA-2, which are encapsulated separately and are both essential for 
infection. CPMV production starts with two plasmids that contain respectively RNA-1 and RNA-2. 
 
Once produced, CPMV can be genetically manipulated to introduce mutations. Moreover, different molecules can be 
chemically linked to the capsid using the reactive side chains of some residues from coat proteins. Infusion can also be 
used to encapsulate molecules using their interaction with the nucleic acid. 
Ligand Receptor CPMV uptake 
Folic acid Folic acid receptor Yes 
Bombesin GRP receptor Yes 
F56 peptide VEGFR-1 No 
Adapted from Steinmetz et al. Copyright 2011 
Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim 
CPMV is easily produced and modified, it has a good bio-distribution and results non-toxic. The route of entry 
to cells expressing surface vimentin is every time more understood. 
 
Drug delivery using CPMV particles could be used in the treatment of cancer, atherosclerosis and 
inflammation in the CNS, as the nanoparticles can target these regions. However, the efficiency of CPMV as a 
drug delivery vehicle and the numerous studies about tumor cell targeting have only been carried out in vitro. 
 
For this reason, it still cannot be confirmed that CPMV particles would preferably internalize into tumor cells 
and release their cargo there, avoiding non desirable side effects in the organism. Further in vivo analyses 
could confirm the advantages in drug delivery using CPMV. 
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Bio-distribution Cell uptake 
Disease treatment Drug delivery 
CPMV can be orally administrated since it 
efficiently traffics from the mice gastrointestinal 
tract into the system circulation and reach any 
tissue. 
Within 30 min after intravenously injection, CPMV is rapidly 
cleared from blood circulation and is found in the liver (>90%) and 
in the spleen (<3%). No toxicity is noticed, although mice present 
a mild leukopenia and an apparent hyperplasia in the spleen. 
CPMV recognizes a cell-surface form of 
vimentin. Cytosolic vimentin is a type III 
intermediate filament, but vimentin has also 
been found in the surface of: 
After interaction with surface vimentin, CPMV is internalized inside 
the cell. A PEG coating can inhibit this uptake. 
• Endothelial, cervical, colon and prostate tumor cells 
 
• Immune system cells, like activated M1 and M2 macrophages 
3. Inflammation in the central nervous 
system (CNS): CPMV can recognize 
regions of inflammation and blood-
brain barrier disruption in the CNS. 
  
2. Atherosclerosis: CPMV targets atherosclerotic plaques and 
M2 macrophages, which are upregulated in atheros-
clerotic lesions.  
1. Cancer: Through vimentin interaction, CPMV targets tumor cells and also M2 
macrophages, which are present in the tumor and are involved in metastasis. 
Moreover, CPMV can be induced to interact with other overexpressed 
receptors in tumors by linking their corresponding ligand to the capsid: 
Two experiments from 2013 have shown the efficiency of CPMV as a 
chemotherapeutic drug delivery vehicle in vitro. In both cases, CPMV uptake was 
due to vimentin interaction and the drug was released in the endolysosome. 
Doxorubicin (DOX) 
Half-live in plasma: 
4-7 min 
 
Maximum time in 
plasma: 30 min Apparent 
hyperpasia 
NO TOXICITY 
Pharmacokinetics Bio-distribution Endocytic uptake and cellular localization 
CPMV-DOX was more 
cytotoxic than free DOX 
 at low dosages 
Proflavine (PF) 
CPMV-PF 
HeLa cells 
killing 
CPMV-PF presented a 
similar efficiency to that 
observed for free PF 
PF 
CPMV-DOX 
HeLa cells 
killing 
HT-29 cells 
killing 
PC-3 cells 
killing 
DOX and PF: Chemotherapeutic drugs 
 
HeLa: Cervical cancer cells 
HT-29: Colon cancer cells 
PC-3: Prostate cancer cells 
Surface 
vimentin 
